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Abstract
The short- and long-term effects of gene therapy using AAV-mediated RPE65 transfer to canine retinal
pigment epithelium were investigated in dogs affected with disease caused by RPE65 deficiency. Results with
AAV 2/2, 2/1, and 2/5 vector pseudotypes, human or canine RPE65 cDNA, and constitutive or tissue-
specific promoters were similar. Subretinally administered vectors restored retinal function in 23 of 26 eyes,
but intravitreal injections consistently did not. Photoreceptoral and postreceptoral function in both rod and
cone systems improved with therapy. In dogs followed electroretinographically for 3 years, responses
remained stable. Biochemical analysis of retinal retinoids indicates that mutant dogs have no detectable 11-cis-
retinal, but markedly elevated retinyl esters. Subretinal AAV-RPE65 treatment resulted in detectable 11-cis-
retinal expression, limited to treated areas. RPE65 protein expression was limited to retinal pigment
epithelium of treated areas. Subretinal AAV-RPE65 vector is well tolerated and does not elicit high antibody
levels to the vector or the protein in ocular fluids or serum. In long-term studies, wild-type cDNA is expressed
only in target cells. Successful, stable restoration of rod and cone photoreceptor function in these dogs has
important implications for treatment of human patients affected with Leber congenital amaurosis caused by
RPE65 mutations.
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Abstract
The short- and long-term effects of gene therapy using AAV-mediated RPE65 transfer to canine
retinal pigment epithelium were investigated in dogs affected with disease caused by RPE65
deficiency. Results with AAV 2/2, 2/1, and 2/5 vector pseudotypes, human or canine RPE65
cDNA, and constitutive or tissue-specific promoters were similar. Subretinally administered
vectors restored retinal function in 23 of 26 eyes, but intravitreal injections consistently did not.
Photoreceptoral and postreceptoral function in both rod and cone systems improved with therapy.
In dogs followed electroretinographically for 3 years, responses remained stable. Biochemical
analysis of retinal retinoids indicates that mutant dogs have no detectable 11-cis-retinal, but
markedly elevated retinyl esters. Subretinal AAV-RPE65 treatment resulted in detectable 11-cis-
retinal expression, limited to treated areas. RPE65 protein expression was limited to retinal
pigment epithelium of treated areas. Subretinal AAV-RPE65 vector is well tolerated and does not
elicit high antibody levels to the vector or the protein in ocular fluids or serum. In long-term
studies, wild-type cDNA is expressed only in target cells. Successful, stable restoration of rod and
cone photoreceptor function in these dogs has important implications for treatment of human
patients affected with Leber congenital amaurosis caused by RPE65 mutations.
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Introduction
Leber congenital amaurosis (LCA) comprises a group of incurable human early onset
genetic retinal degenerative diseases arising from many different molecular defects [1–3].
One form of LCA is caused by mutation of the RPE65 gene, which encodes a protein of the
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retinal pigment epithelium (RPE) with a key role in the cycling of retinoids [4–6]. A
genetically engineered murine model and naturally occurring canine and murine models
with RPE65 deficiency have been studied and used in different treatment strategies [7–16].
Dramatic restoration of vision with gene therapy was first reported in the canine model of
RPE65-associated LCA [7]. The initial investigation involved three homozygous RPE65−/−
affected dogs that each received a surgically delivered subretinal injection of recombinant
adeno-associated virus serotype 2 (AAV2/2) carrying a chicken β-actin-promoter/CMV
enhancer-driven wild-type canine RPE65 cDNA. These results prompted significant
questions in anticipation of translating this preclinical work to humans with RPE65-
associated LCA [17].
The proof-of-principle experiment was confirmed [12,18,19], but questions remain about the
magnitude and predictability of a single AAV-RPE65 subretinal treatment, the
photoreceptor types treated, the long-term stability of visual improvement after a single
treatment, and morphological and biochemical recovery. The present multidisciplinary study
aims to answer such questions in a large group of RPE65−/− affected dogs treated with gene
replacement therapy.
Results and Discussion
In the majority of cases the vector was well tolerated. In four dogs (seven eyes) intraocular
inflammation developed following subretinal (six eyes) or intravitreal (one eye) injection
(see Table 1). Protein gel electrophoresis demonstrated that the vector preparation that
caused the severe ocular inflammation had not been adequately purified (Supplementary
Fig. 1). One of these dogs (BR45) was terminated 7 days postinjection; the intraocular
inflammation in the remaining three dogs was controlled with medical treatment (short-term
systemic and topical corticosteroids and nonsteroidal anti-inflammatory drugs and topical
mydriatics). The eyes of all other dogs in the study, and the eyes of these three dogs after
this initial period, have remained asymptomatic for study periods ranging from 6 months to
longer than 4 years.
Short-Term Restoration of Rod and Cone Function in a Large Cohort of RPE65−/− Affected
Dogs
Electroretinogram (ERG) responses, from 26 eyes of 17 RPE65−/− affected dogs treated
with a single subretinal AAV-RPE65 vector injection, were first evaluated 1–3 months
postinjection and compared to ERGs of 45 untreated eyes of 23 RPE65−/− affected dogs
ages 2–11 months and, in 13 of the dogs, to pretreatment ERGs (Figs. 1A–1C). ERGs
evaluated include those reanalyzed from 2 dogs previously published [7] and now followed
for 3 years after treatment. In normal dogs (n = 9, ages 2–7 months), standard white flashes
(0.4 log scot-cd s m−2) evoke ERGs dominated by rod photoreceptor and postreceptoral
activity under dark-adapted conditions (Fig. 1A, black traces). A cone system component
can be estimated with the use of a rod-desensitizing background light or by presentation of
flashes at a flicker rate (29 Hz) that is too fast for the sluggish rod system to follow; both
estimates are similar in amplitude and time course (Fig. 1A, red traces). RPE65−/− affected
dogs without treatment, or with intravitreal AAV-RPE65, show no detectable ERGs for this
level of stimulation, whereas subretinal AAV-RPE65 can result in rod and cone ERGs that
are normal in waveform but smaller in amplitude (Fig. 1A). We studied function at the level
of rod and cone photoreceptors more precisely with higher energy flashes that saturate the
leading edge of the ERG [20]. In normal dogs, use of a 2000-fold higher flash energy (3.7
log scotcd s m−2) evokes leading edges that saturate in amplitude and peak near 4 ms (Fig.
1B). In this early phase of the waveform, dark-adapted responses are dominated by rod
photoreceptor activity, which results in amplitudes >10 times larger than the cone
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photoreceptor component [20]. Light-adapted responses are dominated by the cone system
because normal dog rods are severely desensitized in this condition [20]. Amplitudes at
these very early times (~4 ms) originate directly from cone photoreceptor activity [21–23].
RPE65−/− affected dogs under dark-adapted conditions showed small but detectable a- and
b-wave ERG components (Fig. 1B). Light-adapted waveforms were unchanged from those
recorded under dark-adapted conditions and, unexpectedly, they could have larger a- and b-
waves than normal dogs (Fig. 1B). The a-wave was exceedingly slow, peaking near 10 ms; a
response was not detectable at the normal time to peak near 4 ms (Fig. 1B). With intravitreal
delivery of AAV-RPE65, ERG shape or amplitude was unchanged. Subretinal delivery of
AAV-RPE65, on the other hand, caused major changes; large signal amplitudes could be
measured at 4 ms under dark- and light-adapted conditions, consistent with restoration of
normal rod and cone photoreceptor sensitivity in a portion of the retina. The b-waves in the
subretinally treated eyes appear to be a combination of appropriately scaled normal and
RPE65−/− affected ERGs. Counterintuitively, ERG photoresponse b-waves in treated eyes
could be smaller under light-adaptation compared to untreated eyes (Fig. 1B).
The ability to detect significant change in an ERG measure with intervention depends
primarily on the expected signal-to-noise ratio (SNR) of that measure. We chose two
measures with similar SNRs (~40 dB) to evaluate functional recovery of rod and cone
systems: the amplitude of the dark-adapted photoresponse at 4 ms for rod function and the
amplitude of light-adapted 29-Hz ERG for cone function (Fig. 1C). None of the 11
intravitreally injected eyes but 23 of 26 subretinally injected eyes showed treatment success
for rod or cone function when using a conservative criterion of mean + 3 SD (Fig. 1C). The
conclusions were unchanged considering rod postreceptoral responses (which also had a
similar SNR) as estimated by the b-wave amplitude of the lower intensity stimulus presented
in the dark (data not shown). A cone photoresponse could be demonstrated upon subretinal
treatment in 8 of the 23 eyes (data not shown); a result consistent with significantly lower
SNR (~20 dB) of this measure compared to the other three measures.
Rod and cone ERGs showed a range of amplitudes in the 23 RPE65−/− affected eyes that
met criteria for treatment success. Twenty eyes had tapetal (superior) or nontapetal (inferior)
locations of the injections; 3 eyes had injections that straddled the two zones. We asked
whether ERG amplitude was related to subretinal injection location and area of the visible
detachment (bleb) documented at surgery and quantified relative to the area of the tapetum.
The bleb areas in the tapetal retina were on average about half as large (mean ± SD = 0.35 ±
0.12) as those in the nontapetal zone (0.69 ± 0.26). ERG amplitudes in the 10 eyes with
tapetal injections were on average higher (rod 43.8 ± 26.5 μV, cone 8.0 ± 6.2 μV) than
those in the 10 eyes with nontapetal injections (rod 28.5 ± 13.3 μV, cone 5.6 ± 2.5 μV). Rod
ERG amplitude as a function of the subretinal injection area was much larger in the superior
(tapetal) retina compared to the inferior retina (124.7 ± 46.4 versus 44.9 ± 22.8 μV/tapetal
area, P < 0.01). The two groups of eyes with different injection sites were similar in terms of
other parameters (age at injection, vector serotype, promoter, dose, and volume). Taken
together, these regional retinal differences between treatment responses suggest a
predictable behavior based on different photoreceptor densities in these retinal areas [24].
Long-Term Restoration of Rod and Cone Function
Two dogs from the previous proof-of-principle study [7] had yearly ERG recordings to
determine the long-term functional consequences of single subretinal and intravitreal
injections. ERGs recorded at 1, 2, and 3 years after the unilateral subretinal injection of
AAV-RPE65 in BR33 demonstrate the stability of the functional rescue (Figs. 1D and 1E).
Specifically, rod and cone ERG responses to a 0.4 log scot-cd s m−2 flash were undetectable
before treatment, became sizeable posttreatment, and have remained so for 3 years. Near
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normal sensitivity was restored to a fraction of rod and cone photoreceptors across the
retina, as demonstrated by responses at the 4-ms time point, and these responses were stable
through 3 years of follow-up (Fig. 1E). The results were similar in BR47, the second dog
with unilateral subretinal treatment (Fig. 1F). Over this period, ERG responses from the
intravitreally injected fellow eye of both these dogs were stable and remained within the
range expected from untreated RPE65−/− affected eyes.
11-cis-Retinal is Localized to Treated Retinal Regions
In samples of retina plus RPE/choroid from normal canine eyes, the major retinoid
component was 11-cis-retinal (2.8 and 2.6 nmol/eye in two dogs). Minor components
included retinyl esters (<100 pmol), all-trans-retinal (<250 pmol), and all-trans-retinol (<250
pmol). In the two normal eyes, there appeared to be no major differences in rhodopsin
content (as measured by 11-cis-retinal) and no differences in the accumulation of retinyl
esters in the different retinal regions sampled, although the superior central sector did have
about twice the rhodopsin content of other regions.
Samples of retina plus RPE/choroid from eyes of RPE65−/− affected dogs, either untreated
or after intravitreal injections of AAV-RPE65, had retinyl ester content that was
dramatically (1000- to 10,000-fold) elevated compared to normal controls. This increase
appeared age dependent (1.4–2.2 nmol/eye for BR132 (age 3 months) and 35 ± 8 nmol/eye
for other dogs (ages 10 to 25 months); Figs. 2A–2C, Supplementary Table 1).
Samples of retina plus RPE/choroid from eyes of RPE65−/− affected dogs, either untreated
or after intravitreal injections of AAV-RPE65, had no measurable 11-cis-retinal. Recovery,
assessed by the presence of 11-cis-retinal, occurred in eyes that had received subretinal
injections of AAV-RPE65 (Supplementary Table 1). The recovery was not diffuse across the
retina but restricted to the region of the subretinal injection (Fig. 2D, Supplementary Table
1). There was no significant amount of 9-cis-retinal. The small amounts detected are likely
the product of isomerization during sample preparation and they are well below recovered
11-cis-retinal production. (The small peak marked with the blue arrow could not be
positively identified as 9-cis-retinal oxime [25].) There were no dramatic differences in
retinyl ester levels in the recovered retinal regions compared to surrounding regions within
14 months posttreatment.
In four eyes of two RPE65−/− affected dogs (BR74, BR111; Supplementary Table 1), we
assessed functional retinal recovery by both retinoid content and ERG function. In one eye
of each animal (BR74OD, BR111OS), the subretinal injection was in the superior tapetal
retina. Based on rod and cone function, we considered these two eyes treatment successes.
Retinoid results were concordant; and the superior retinal location of detectable 11-cis-
retinal was consistent with the site of subretinal injection (see above and Supplementary
Table 1). The right eye of BR111 had an intravitreal injection of AAV-RPE65 and showed
no difference in rod and cone function or retinoids compared with untreated RPE65−/−
affected dogs. The left eye of BR74, however, had an inferior subretinal injection of AAV-
RPE65 and rod and cone function did not meet the criteria established for treatment success.
Retinoid analyses, however, detected inferior retinal 11-cis-retinal, at about 10-fold fewer
pmol/area than the highest amounts found in the superior retina of BR74OD or BR111OS.
This suggests that at least one of the three eyes not appreciable as a treatment success by
full-field rod and cone functional analyses did have measurable although lesser success, as
assayed by the retinoid analyses.
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Preservation of Photoreceptor Structure and Expression of RPE65 in Treated Eyes
Young, affected untreated dogs showed only two abnormalities: very slight disorganization
of the photoreceptor outer segments and the accumulation of lipoidal inclusions in the RPE.
Photoreceptor length was normal, and there was no photoreceptor degeneration or cell loss
present at this age (Fig. 3, compare 3A and 3B with 3C and 3D). The RPE lipid inclusions
were distinct and increased in size and number with age, but their distribution throughout the
monolayer was not uniform. Older affected dogs showed similar photoreceptor changes in
the superior tapetal region. In the nontapetal region, however, the photoreceptor
abnormalities were more severe; there was outer segment shortening and disorganization
and loss of one or two rows of nuclei from the outer nuclear layer (data not shown). Unlike
the normal retina, which showed very intense and uniform labeling limited to the RPE with
the anti-RPE65 antibody, the mutant RPE was not labeled (Fig. 3, compare 3G and 3H with
3I and 3J); the opsin antibody and peanut agglutinin (PNA) lectin gave similar labeling
results in normal and mutant retinas (Figs. 3G–3J).
Eyes receiving intravitreal vector injections showed no RPE65 immunolabeling in the RPE
or retina, and the retinal structure was similar to that of the untreated eyes of similar age or
untreated areas of eyes receiving subretinal vector. Inner retinal layers, particularly the
ganglion cell layer, showed no RPE65 labeling. In contrast, eyes receiving subretinal vector
showed very distinct RPE65 labeling limited to the RPE cells of the treated area (Figs. 3K,
3L, 3P, 3R, 3T, 3V; Supplementary Fig. 2 (movie)). With two exceptions, no other cells
showed RPE65 protein expression after treatment. In one dog, there was multifocal labeling
of tapetal cells (data not shown); in a second dog, one rod cell showed diffuse RPE65
cytoplasmic labeling (Figs. 3M and 3N). Treated areas showed normal morphology of
photoreceptor outer segments in both the tapetal and the nontapetal regions (Figs. 3E and
3F). Because of the variability in size and number of lipid inclusions, and the limitations of
analysis using conventional retinal sections, we did not attempt to determine if treatment
resulted in changes in the size and number of these inclusions. There were no appreciable
differences in the thickness of the nuclear layers for comparable regions of normal, affected,
and treated affected retinals (Fig. 3; Supplementary Fig. 2), which reflects both an absence
of untoward effect of therapy and the very slow course of the natural disease.
RPE65 immunolabeling following subretinal injections was limited to the treated areas, but
the intensity and extent of labeling were not equal in all eyes. In some, the distribution of
RPE65 protein was restricted to a small area within the treated regions, while other eyes
showed a wider distribution and intensity of RPE65 labeling. In general, eyes that were
considered to have a very good bleb following injection had RPE65 labeling that covered a
larger area of the treated monolayer and showed more intense labeling. Conversely, eyes
with poor postinjection blebs had more restricted and less intense labeling. In one dog
(BR53), there were greater amplitudes of rod and cone ERGs in the left eye compared with
those of the right eye. In part, this may reflect the larger bleb observed in the left eye (Fig.
3S) compared to the right (Fig. 3O). Correspondingly, RPE65 immunolabeling showed more
intense and diffuse RPE labeling in the left eye (Figs. 3S–3V) compared to the right (Figs.
3P–3R). The right eye of BR53 showed some regions with intense immunolabeling (Fig. 3R;
Supplementary Fig. 2), which suggests that within such regions functional restoration had
been achieved.
Serology
Sera from all dogs studied exhibited increased immunoreactivity with the AAV2/2 antigen
compared to serum from the unimmunized pup. Some, but not all, adult dogs had especially
high pretreatment immunoreactivity to AAV2/2. For example, BR119 and BR81 had high
pretreatment serum antibodies, whereas BR33, BR61, BR122, and BR114 did not. Serum
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immunoreactivity to AAV2/2 increased in all animals injected intraocularly with AAV2/2-
RPE65, but was especially elevated in those animals with high pretherapy serology.
Increases were not dependent on site of delivery of AAV-RPE65 (intravitreal versus
subretinal). For example, BR85 (which had bilateral intravitreal injections) had (mild)
increases similar to those of BR53 (which had bilateral subretinal injections). A comparison
of ERG results from two dogs without high pretreatment serum antibodies and the two dogs
with high antibodies indicated that there was no major difference in success level.
All intraocular fluid samples lacked immunoreactivity to AAV2/2 prior to treatment. There
were only mild increases in immunoreactivity posttreatment in a few of the dogs/eyes (for
example, right eye of BR81, both eyes of BR119 and BR53). As expected, there were no
significant increases in immunoreactivity of serum or intraocular fluids after intraocular
injection of an AAV with a capsid different from that of AAV2/2 (i.e., AAV2/5, AAV2/1).
All sera and intraocular fluid samples tested yielded essentially identical ELISA results for
GST versus GST-RPE65 antigen, indicating that there is no specific anti-body response to
RPE65 antigen. This was true even for samples from animals that had exhibited strong
inflammatory responses after ocular gene therapy with AAV-RPE65. Western analysis also
yielded no evidence for any specific antibody response to RPE65 in sera or intraocular fluids
after subretinal injection of AAV-RPE65 (data not shown), confirming the ELISA results.
Continuing studies to examine specifically the results of repeated therapy will address these
issues more fully.
Extraocular Transgene Expression
PCR and RT-PCR analyses of frozen tissue from kidney, heart, lung, liver, lymph nodes,
bone marrow, ovary/testis, brain (cortex), and extraocular muscle harvested terminally
(several months to approximately 1 year posttherapy) revealed no evidence of extraocular
presence or expression of the wild-type RPE65 cDNA. Immunocytochemistry revealed no
evidence of RPE65 protein in optic nerves of treated dogs (data not shown).
This study confirms and amplifies previous findings that a single dose of subretinally
delivered recombinant adeno-associated virus carrying an appropriately promoted wild-type
RPE65 cDNA can restore vision in the canine model of RPE65-associated LCA and that
intravitreally administered vector does not. The degree of visual restoration as assessed by
analysis of electroretinographic responses was not influenced to any obvious extent by either
the specific vector used among five different combinations of promoter, vector pseudotype,
species (canine, human) of cDNA, or even (over approximately 2 log units) the dose of
vector used. It is important to note that 3 of 26 eyes that were considered to have good
postinjection blebs did not result in treatment success as assessed by conservative ERG
measures of rod and cone function. The reasons for these failures are not clear at this time,
but could involve sensitivity of a retina-wide test to detect a focal treatment, leakage of
vector out of the bleb, or sub-RPE delivery.
Recovery of retinal function was strictly limited to the treated eye in dogs receiving
unilateral subretinal gene therapy. Furthermore, biochemical and immunochemistry data
agree that only the area treated directly by subretinal injection regains functional RPE65
expression and 11-cis-retinal production. This is also concordant with previous results
demonstrating, by genomic PCR, that viral DNA persists only in the neural retina and RPE/
choroid of the injected quadrant [7].
Even though we used vector pseudotypes and promoters that potentially target multiple cell
types, we observed expression of RPE65 protein, as determined by immunocytochemistry,
only in RPE cells, except for one lone rod photoreceptor. Absence of RPE65 protein from
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canine ganglion cells, in eyes treated subretinally or intravitreally, is concordant with results
in mice treated similarly [15], but contrasts with intravitreal injection of AAV.CMV.EGFP,
which results in EGFP production in canine and mouse ganglion cells [26]. These results
suggest that production of stable RPE65 protein requires a specific cellular environment and
that future studies to explore this issue are clearly needed.
Apart from one episode with a batch of vector that was inadvertently incompletely purified
(Supplementary Fig. 1), we observed no significant inflammatory or other deleterious effects
of the therapy. Moreover, even eyes suffering inflammation from impure vector eventually
responded to medication and demonstrated significant restoration of vision. All dogs
retained for long-term evaluation have remained healthy, with no medication required after
the immediate posttherapy period. Such results are in accord with other safety studies of
subretinal rAAV in dogs [27]. At present, one dog is 5 years out from the date of therapy,
and six are between 2 and 4 years. These are very significant periods in terms of the canine
life span, with no evidence of untoward result of the therapy. The visual recovery assessed
by ERG has shown no sign of decrement at the time points measured, indicating that, at the
retinal level, the recovery of rod and cone photoreceptor function is stable.
In general, biochemical and immunochemistry results have been congruent with the
functional assessment by ERG. Interestingly, in one eye we found biochemical evidence of
11-cis-retinal production but no statistically significant difference in ERG parameters in this
eye compared with untreated eyes. This observation may have implications for potential
therapy monitoring in human patients, if improved visual perception occurs in retinal
regions too small to be detected by a full-field measurement of retinal function such as the
ERG. In anticipation of such treatment effects, strategies have recently been devised to
detect small regional changes in visual thresholds in humans with LCA [17,28].
Materials and Methods
Animals
Forty dogs were studied. Twenty-eight dogs homozygous for the canine RPE65 mutation
(Table 1), and 1 unaffected control (Table 1), were part of a research strain of mixed-breed
dogs maintained at the Retinal Disease Studies Facility (Kennett Square, PA, USA). The
disease in this strain derives from a single affected briard dog and is caused by a 4-bp
deletion in the canine RPE65 gene, as described previously [13]. Molecular diagnostic
testing has determined that this strain is homozygous normal for other genes/loci responsible
for inherited retinal degeneration in dogs (prcd, erd, CNGB3, PDE6B, Rho, RPGR). Two
purebred briard dogs (Exp1817, Exp2818; Table 1), affected by the same RPE65 mutation
as the colony dogs, were also studied as affected, untreated controls. In addition, 14 eyes
from 9 normal control dogs were used for ERG studies. All procedures involving animals
were undertaken in accordance with the guidelines of the U.S. Public Health Service’s
policy on the humane care and use of laboratory animals. Twenty-nine eyes of 19 affected
dogs each received a single subretinal injection containing a therapeutic vector (Table 1); 26
of these eyes (17 dogs) were subsequently tested at least once by ERG. Fourteen eyes of 11
affected dogs (Table 1) received an intravitreal injection of vector, a sham injection, or no
injection, and subsequently each of these eyes was also tested at least once by ERG. Eyes
were harvested at selected time points posttherapy to evaluate the results of treatment by
morphology, immunohistochemistry, retinoid analyses, and molecular studies (Table 1).
Thirty-seven eyes from 22 dogs were harvested for morphological evaluation, including 21
for immunohistochemical examination (Table 1). These included 4 eyes from the 2 purebred
affected briard dogs and 33 eyes from 20 colony dogs. Eighteen of these eyes had each
received a subretinal vector injection, 7 had received an intravitreal injection, and 12
(including the 4 purebred briard eyes) had received no therapy.
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Vectors
Five types of therapeutic AAV vectors, identified as AAV2/2-CBA-cRPE65, AAV2/5-
CBA-hRPE65, AAV2/2-CBA-hRPE65, AAV2/1-CBA-hRPE65, and AAV2/1-RPE08-
hRPE65, were used (Table 1). All vectors are flanked by 143-bp AAV2 inverted terminal
repeats and contain a 199-bp SV40 polyadenylation signal sequence. AAV2/2, AAV2/1, and
AAV2/5 vectors are packaged into serotype 2, 1, or 5 capsids, respectively. CBA indicates
the 1680-bp hybrid chicken β-actin promoter, encompassing a cytomegalovirus immediate
early enhancer (381 bp), the proximal chicken β-actin promoter (283 bp), and the chicken β-
actin intron 1 flanked by exon 1 and exon 2 sequences [29]. RPE08 is an 823-bp human
RPE65-specific promoter (−1 to −822). cRPE65 is a 1656-bp canine RPE65 cDNA, and
hRPE65 is a 1602-bp human RPE65 cDNA. AAV2/1-CBA-hRPE65 also contains a 594-bp
woodchuck hepatitis virus posttranscriptional element. All AAV vectors were produced and
purified identically according to Zolotukhin et al. [30,31] but with modifications. HEK 293
cells (ATCC) were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 5% fetal bovine serum and antibiotics. A CaPO4 transfection
precipitation was set up by mixing a 1:1 molar ratio of the rAAV vector plasmid and the
helper plasmid pDG(4), which contained all the helper functions required for production of
the vector, including the desired AAV serotype capsid gene. For serotype 2 vectors the
capsid gene was from wild-type serotype 2 AAV; for serotype 1 vector a pseudotyped virus
was produced with a helper plasmid containing an AAV serotype 1 capsid gene, and for the
serotype 5 vector a pseudotyped virus was produced with helper plasmid containing an AAV
serotype 5 capsid gene. For each vector the appropriate two-plasmid DNA precipitate was
added to 1100 ml of DMEM and the mixture applied to 293 cell monolayers in a cell factory
(Nalge Nunc International, Rochester, NY, USA). The transfection was allowed to incubate
at 37°C for 60 h, after which the cells were harvested and lysed by three freeze/thaw cycles.
The crude lysate was clarified by centrifugation and the resulting vector-containing
supernatant divided between four discontinuous iodixanol step gradients and run at
350,000g for 1 h. Five milliliters of each 60–40% step interface was removed, and the
combined vector fractions were further purified and concentrated by column
chromatography on a 5-ml HiTrap, Q Sepharose column using a Pharmacia ATKA FPLC
system. The vector was loaded in 20 mM NaCl, pH 8.0, and eluted from the column using a
500 mM NaCl, pH 8.0, step gradient. The appropriate eluted fractions were then pooled and
concentrated and the buffer was exchanged with PBS in a Biomax 100K concentrator
(Millipore, Billerica, MA, USA). Vector purity was assessed by silver-stained SDS–
polyacrylamide gel electrophoresis [30]. Each vector was titered for physical particles by
quantitative competitive PCR [32] and AAV vectors were then stored at −80°C in PBS prior
to use.
Surgical procedures and postsurgical treatment and evaluation
Five cubic centimeters of blood for baseline serology studies was collected by venipuncture
prior to treatment, and then animals were anesthetized with thiopental/isoflurane. Subretinal
injections were performed as described [7,32] after injecting 5–10 cc sterile saline retro-
orbitally to prevent rotation of the eye. Briefly, after mydriasis, an anterior chamber
paracentesis was performed with a 30-gauge needle to provide space for the vector and to
obtain fluid for baseline intraocular antibody measurements. A 30-gauge anterior chamber
cannula (Storz) was inserted through a sclerotomy incision and gently pressed against the
neural retina at the desired injection site. A dose volume between 100 and 200 μl was
delivered subretinally, thereby creating a localized dome-shaped retinal detachment
(“bleb”). The vector dose delivered ranged from approximately 1010 to 1012 particles. The
retinal location of the bleb was observed at the time of surgery and documented by indirect
ophthalmoscopy, fundus drawings, and photography. Retinal vessels were assessed to ensure
that they remained well perfused during and following the procedure. Four milligrams of
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Kenalog (triamcinolone acetonide; 40 mg/ml; Bristol–Meyers–Squibb, New York, NY,
USA) was injected subconjunctivally, and PredG ointment (Allergan Pharmaceuticals,
Irvine, CA, USA) was applied to the corneas while the animals recovered from anesthesia.
Following surgery, the dogs were monitored by routine clinical ocular examinations using
binocular indirect ophthalmoscopy and biomicroscopy after mydriasis (1% tropicamide);
flattening of the subretinal bleb or presence of ocular inflammation was recorded.
Immediately following surgery, retinal location and extent of the area of subretinal treatment
injection, apparent as a bleb at the time of the surgery, was documented with indirect
ophthalmoscopy and fundus drawings. The area of the bleb was quantified from the
drawings and specified as a (unitless) fraction of the area of a standard tapetal zone. The
location of the injection area was specified as superior (tapetal) or inferior (nontapetal) in
most cases; in some eyes, however, the injection area was on the boundary between tapetal
and nontapetal zones and was specified as such.
Electroretinography
Dogs were dark-adapted overnight and anesthetized as described [7,20]. Pupils were dilated
(cyclopentolate, 1%; phenylephrine,10%), and pulse rate, oxygen saturation, and
temperature were monitored. Full-field ERGs were recorded with Burian–Allen contact lens
electrodes and a computer-based system. Low-energy (10 μs duration; maximum luminance
of unattenuated white flash 0.4 log scot-cd s m−2) and high-energy (1 ms duration;
maximum luminance of unattenuated white flash 3.7 log scot-cd s m−2) flashes were used
under dark-adapted and light-adapted (1.5 log cd m−2 at 1-Hz stimulation, 0.8 log cd m−2 at
29-Hz stimulation) conditions [7,20].
Retinoid analysis
Dark-adapted dogs were euthanized and enucleated (all procedures performed under dim red
light). Retina, separated from RPE, was divided into six sectors, three from the superior
tapetal zone and three from the inferior nontapetal zone. Tissue samples were double
wrapped in aluminum foil and stored at −80°C until use. All experimental procedures related
to the analysis, derivatization, and separation of retinoids were undertaken as described
previously for mouse eyes [8,9] with minor modifications as described below. Prior to
extraction, retinals were derivatized to oximes with hydroxylamine for better separation
under our chromatographic conditions. Retinoid analysis was performed on an Agilent 1100
series high-pressure liquid chromatograph (HPLC) equipped with a diode array detector and
Agilent Chemstation A.10.01 software. A normal-phase column (Beckman Ultrasphere Si
5μ, 4.6 × 250 mm) and an isocratic solvent system of 0.5% ethyl acetate in hexane (v/v) for
15 min followed by 4% ethyl acetate in hexane for 65 min at a flow rate of 1.4 ml/min at
20°C (total 80 min) with detection at 325 nm were used.
Histopathology and immunocytochemistry
Thirty-seven eyes were studied morphologically from 20 affected dogs, purposely bred for
these studies, and 2 affected purebred briard dogs (4 and 10.5 months of age). These
included 18 eyes receiving subretinal injections, 7 receiving intravitreal injections, and 12
receiving no therapy (Table 1). Posttreatment intervals ranged from 3.5 months to 2 years.
Retinal sections for morphologic studies were prepared using a triple fixation protocol [33]
prior to embedding in plastic, a 4% paraformaldehyde fixation for OCT embedding and
immunocytochemistry [34], or Bouin’s solution followed by processing for standard paraffin
embedding and sectioning for histopathological examination and immunochemistry. For
treated eyes, plastic- or OCT-embedded tissues were oriented such that the sections
extended through the center of the treated area; untreated areas from adjoining and other
quadrants were also included for analysis. For immunocytochemical studies, sections from
OCT-embedded retinas were labeled with rabbit anti-mouse RPE65 polyclonal antibody
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(PETLET; gift from Dr. Michael Redmond), monoclonal antibody K16-107C directed at the
C-terminal domain of opsin [35], DAPI, and/or PNA to label the insoluble extracellular
domain surrounding the cones [36]. Secondary antibodies included goat anti-rabbit IgG
conjugated to either Alexa Fluor 488 (green) or Alexa Fluor 568 (red) and goat anti-mouse
IgG conjugated to Alexa Fluor 568 (Molecular Probes, Eugene, OR, USA). Sections were
examined with a Zeiss Axioplan microscope using epifluorescence and DIC optics. Images
were digitally captured (Spot 3.3; Diagnostic Instrument, Inc., Sterling Height, MI, USA)
and imported into Adobe Photo-Shop (Adobe Systems, San Jose, CA, USA).
Samples for serology, virology, and extraocular transgene expression
Serum samples were obtained from all dogs receiving therapy, immediately prior to surgery,
by venipuncture 3 weeks after injection and, again, terminally. Conjunctival swabs for viral
isolation were taken at multiple time points following surgery. Following euthanasia with a
pentobarbital overdose, eyes that were enucleated for other studies had fluid samples
collected from the anterior chamber and vitreous. All samples were stored at −80°C until
used for immunology studies.
Immunology: ELISA to determine Anti-RPE65 antibody response after AAV-RPE65 gene
therapy
Antigen was prepared from human RPE65 cDNA amplified from plasmid pAAV2.1CMV-
hRPE65 [38] using forward primer 5′-
AGGAATTCCATGTCTATCCAGGTTGAGCATC-3′ and reverse primer 5′-
CAGAATTCTCAAGATTTTTTGAACAGTCCATG-3′. The 1.6-kb product was digested
with EcoRI and subcloned into pGEX3X (Pfizer, New York, NY, USA), creating an in-
frame fusion of hRPE65 with GST. Both GST-hRPE65 and GST (control) proteins were
expressed in BL21 Codon-Plus RIL bacteria (Stratagene, La Jolla, CA, USA). Five
milliliters of an overnight culture was used to inoculate 200 ml LB broth; bacterial pellets
were washed with PBS and resuspended in 20 ml of lysis buffer (5% lithium dodecyl
sulfate, 10 mM Tris, pH 8.2) supplemented with protease inhibitors. DNA was removed by
passing the lysates over a column of 425–600 μm-sized, acid-washed glass beads (Sigma
Chemical Co., St. Louis, MO, USA). Cleared lysates were aliquoted and stored at −80°C. To
verify hRPE65 expression, each bacterial lysate was run on a 10% Bis-Tris NuPAGE gel
(Invitrogen, Carlsbad, CA, USA) with Mops running buffer and then electroblotted onto
Hybond ECL (Amersham, Piscataway, NJ, USA). The blot was probed with 1:1000 diluted
rabbit anti-RPE65 antiserum (PETLET), followed by 1:2000 diluted, HRP-conjugated,
donkey anti-rabbit immunoglobulin (Amersham) and finally ECL Plus detection reagent
(Amersham). A band of approximately 90 kDa was detected in lanes containing GST-
RPE65 lysates and was absent in lanes containing only GST lysates. The ELISA validation
assay demonstrated that the reaction conditions tested specifically for antibodies to RPE65.
ELISA validation assay
One hundred microliters of antigen (1:100 dilution in 0.1 M sodium bicarbonate, pH 9.6)
was aliquoted per well of a 96-well high-binding EIA/RIA plate (Corning, Corning, NY,
USA) and incubated overnight at 4°C. After coating with antigen, the wells were blocked
with 1% BSA and sequentially incubated with 1:2000 diluted rabbit anti-RPE65 antiserum
(PETLET) or control rabbit anti-β-galactosidase antiserum (Chemicon, Temecula, CA,
USA), followed by 1:2000 diluted, HRP-conjugated, donkey anti-rabbit immunoglobulin
(Amersham) and p-phenylenediamine dihydrochloride substrate (Sigma–Aldrich Corp., St.
Louis, MO, USA). Between steps, the wells were washed with 0.05% Tween 20 in PBS. The
OD490 was determined after quenching with H2SO4 using a plate reader (Wallac Victor,
Perkin–Elmer, Boston, MA, USA).
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Analysis of sera, anterior chamber fluid, and vitreous of treated dogs
Samples from all animals were screened for immunoreactivity to RPE65 protein. Serum
from an untreated 3-week-old unimmunized puppy was used as a negative control. All
samples were stored at −80°C from the time of collection until their use. The GST and GST-
RPE65 test antigen preparations as well as LCI-GP parvo/distemper vaccine (positive
control; Fort Dodge Animal Health Division of Wyeth) were diluted 1:100 in 0.1 M sodium
bicarbonate, pH 9.6, and 100 Al of diluted antigen was aliquoted per well of a 96-well high-
binding EIA/RIA plate (Corning) and incubated overnight at 4°C. After being coated with
antigen, the wells were blocked with 1% BSA and sequentially incubated with 1:50 diluted
specimen and subsequently analyzed as above.
Western blot
To confirm the results obtained by ELISA, sera from positive (AAV-treated; BR29) and
negative (untreated and unimmunized puppy) control dogs were used as probes for Western
analysis. Results were compared with a blot probed with rabbit anti-RPE65 antiserum. One
microliter of each antigen was run in triplicate on a 10% Bis-Tris NuPAGE gel (Invitrogen)
with Mops running buffer and then electroblotted onto Hybond ECL (Amersham). The blots
were probed with 1:200 diluted dog serum or 1:1000 diluted rabbit anti-RPE65 antiserum;
followed by 1:2000 diluted, HRP-conjugated, sheep anti-dog immunoglobulin (Sigma) or
donkey anti-rabbit immunoglobulin (Amersham) and ECL Plus detection reagent
(Amersham).
Immunology: antibodies to AAV2/2
Samples were analyzed for anti-bodies to AAV type 2 capsid proteins. Enhanced protein
binding ELISA plates (Costar, Corning, NY, USA) were coated for 2 h at room temperature
with antigen using 1.8 × 109 particles/well of AAV2/2 in bicarbonate buffer, pH 9.6. Plates
were then washed, blocked, and incubated with diluted (1:20, 1:100) serum and intraocular
fluid. Saline and serum from an uninjected, unimmunized puppy were used as negative
controls. Samples were applied to wells in triplicate and were incubated overnight at 4°C.
Human serum containing high levels of anti-AAV2/2 antibodies served as a positive control.
Samples were then washed and incubated for 2 h at room temperature with a 1:1000 dilution
of alkaline phosphatase-conjugated rabbit anti-dog IgG (Sigma, 100 Al/well). After
washing, color was developed using Sigma Fast paranitrophenyl phosphate substrate
(Sigma). The plates were read at an optical density at 405 nm.
Molecular analyses of extraocular transgene expression
Sera, samples from conjunctival swabs, and other frozen organ tissues were analyzed for the
presence of RPE65 transcript, by RT-PCR, or transgene, by PCR. For RT-PCR studies of
frozen extraocular tissues, RNA was extracted from 5–10 mg of tissue using the RNeasy
Mini Kit (Qiagen, Inc., Valencia, CA, USA), and RNA (10 ng) was subsequently reverse
transcribed and PCR was performed to amplify a segment of the canine RPE65 cDNA. Two
sets of primers were used in two different reactions, using the GeneAmp RNA PCR Kit
(Applied Biosystems, Foster City, CA, USA). An RT-PCR assay was designed to
discriminate wild-type RPE65 transcript from that containing the briard mutation. Forward
primer 5′-CATAACGGAATTTGGCACCT-3′ (JB7) and reverse primer 5′-
CAGGGGAATTGTACGACGAC-3′ (JB8) amplify a 219-bp product from canine cDNA.
The forward primer overlaps the briard deletion and amplifies only wild-type RPE65 when
the primer is annealed at 10–12°C above its Tm. A second set of primers (5′-
CATAACGGAATTTGGCACCT-3′ (JB5) and 5′-CAGGGGAATTGTACGACGAC-3′
(JB6)) flanks the region containing the briard deletion and amplifies a 396-bp product from
both wild-type and mutant RPE65 under the same PCR conditions. PCR was carried out for
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40 cycles with annealing at 51°C for 30 s and extension at 72°C for 1 min per cycle with a
final extension of 10 min at 72°C. The PCR products were resolved on a 2% agarose gel.
Additional PCRs designed to amplify the wild-type AAV REP DNA sequence were
performed using primers forward 5′-TCCTTCAATGCGGCCTC-3′ and reverse 5′-
TCATCTTCCCCTCCTCC-3′. PCR was carried out for 36 cycles with annealing at 57°C
for 1 min and extension at 72°C for 1 min per cycle with a final extension of 10 min at
72°C.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This work was supported by the NIH (U10EY13729, EY06855, EY11123, EY13385, EY13132, EY08061), The
Foundation Fighting Blindness, The ONCE International Prize for R&D in Biomedicine and New Technologies for
the Blind, Research to Prevent Blindness, Inc., and the Macula Vision Research Foundation. Technical assistance
from Amanda Nickle, Gerri Antonini, and the staff at the RDSF and from Pam Hammond and Julie Jordan at
Cornell is gratefully acknowledged. We thank Keith Watamura for invaluable graphics support. We are grateful for
the critical help of V. Bhuva, A. Cheung, J. P. Van Hooser, M. Batten, and O. Bond. T. M. Redmond generously
provided the RPE65 antibody.
References
1. Hanein S, et al. Leber congenital amaurosis: comprehensive survey of the genetic heterogeneity,
refinement of the clinical definition, and genotype–phenotype correlations as a strategy for
molecular diagnosis. Hum. Mutat. 2004; 23:306–317. [PubMed: 15024725]
2. Preising MN, Heegard S. Recent advances in early-onset severe retinal degeneration: more than just
basic research. Trends Mol. Med. 2004; 10:51–54. [PubMed: 15106616]
3. Cremers FP, van den Hurk JA, den Hollander AI. Molecular genetics of Leber congenital amaurosis.
Hum. Mol. Genet. 2002; 11:1169–1176. [PubMed: 12015276]
4. Thompson DA, Gal A. Vitamin A metabolism in the retinal pigment epithelium: genes, mutations,
and diseases. Prog. Retinal Eye Res. 2003; 22:683–703.
5. Baehr W, et al. The retinoid cycle and retinal disease. Vision Res. 2003; 43:2957–2958. [PubMed:
14611932]
6. McBee JK, et al. Confronting complexity: the interlink of phototransduction and retinoid
metabolism in the vertebrate retina. Prog. Retinal Eye Res. 2001; 20:469–529.
7. Acland GM, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat.
Genet. 2001; 28:92–95. [PubMed: 11326284]
8. Van Hooser JP, et al. Rapid restoration of visual pigment and function with oral retinoid in a mouse
model of childhood blindness. Proc. Natl. Acad. Sci. USA. 2000; 97:8623–8628. [PubMed:
10869443]
9. Van Hooser JP, et al. Recovery of visual functions in a mouse model of Leber congenital amaurosis.
J. Biol. Chem. 2002; 277:19173–19182. [PubMed: 11897783]
10. Veske A, et al. Retinal dystrophy of Swedish briard/briard-beagle dogs is due to a 4-bp deletion in
RPE65. Genomics. 1999; 57:57–61. [PubMed: 10191083]
11. Redmond TM, et al. RPE65 is necessary for production of 11-cis-vitamin A in the retinal visual
cycle. Nat. Genet. 1998; 20:344–351. [PubMed: 9843205]
12. Narfstrom K, et al. Functional and structural recovery of the retina after gene therapy in the RPE65
null mutation dog. Invest. Ophthalmol. Visual Sci. 2003; 44:1663–1672. [PubMed: 12657607]
13. Aguirre GD, et al. Congenital stationary night blindness in the dog: common mutation in the
RPE65 gene indicates founder effect. Mol. Vision. 1998; 4:23.
14. Gouras P, Kong J, Tsang SH. Retinal degeneration and RPE transplantation in Rpe65−/− mice.
Invest. Ophthalmol. Visual Sci. 2002; 43:3307–3311. [PubMed: 12356839]
Acland et al. Page 12
Mol Ther. Author manuscript; available in PMC 2013 May 08.
15. Dejneka NS, et al. In utero gene therapy rescues vision in a murine model of congenital blindness.
Mol. Ther. 2004; 9:182–188. [PubMed: 14759802]
16. Pang J, et al. Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human
Leber congenital amaurosis (LCA). Mol. Vision. 2005; 11:152–162.
17. Jacobson SG, et al. Identifying photoreceptors in blind eyes due to RPE65 mutations: prerequisite
for human gene therapy success. Proc. Natl. Acad. Sci. USA. 2005 (online publication ahead of
print).
18. Narfstrom K, et al. In vivo gene therapy in young and adult RPE65−/− dogs produces long-term
visual improvement. J. Hered. 2003; 94:31–37. [PubMed: 12692160]
19. Ford M, et al. Gene transfer in the RPE65 null mutation dog: relationship between construct
volume, visual behavior and electroretinographic (ERG) results. Doc. Ophthalmol. 2003; 107:79–
86. [PubMed: 12906125]
20. Kijas JW, et al. Naturally occurring rhodopsin mutation in the dog causes retinal dysfunction and
degeneration mimicking human dominant retinitis pigmentosa. Proc. Natl. Acad. Sci. USA. 2002;
99:6328–6333. [PubMed: 11972042]
21. Cideciyan AV, Jacobson SG. An alternative phototransduction model for human rod and cone
ERG a-waves: normal parameters and variation with age. Vision Res. 1996; 36:2609–2621.
[PubMed: 8917821]
22. Robson JG, Saszik SM, Ahmed J, Frishman LJ. Rod and cone contributions to the a-wave of the
electroretinogram of the macaque. J. Physiol. 2003; 547:509–530. [PubMed: 12562933]
23. Mahroo OA, Lamb TD. Recovery of the human photopic electroretinogram after bleaching
exposures: estimation of pigment regeneration kinetics. J. Physiol. 2004; 554:417–437. [PubMed:
14594984]
24. Kemp CM, Jacobson SG. Rhodopsin levels in the central retinas of normal miniature poodles and
those with progressive rod–cone degeneration. Exp. Eye Res. 1992; 54:947–956. [PubMed:
1521585]
25. Fan J, Rohrer B, Moiseyev G, Ma JX, Crouch RK. Isorhodopsin rather than rhodopsin mediates
rod function in RPE65 knock-out mice. Proc. Natl. Acad. Sci. USA. 2003; 100:13662–13667.
[PubMed: 14578454]
26. Dudus L, et al. Persistent transgene product in retina, optic nerve and brain after intraocular
injection of rAAV. Vision Res. 1999; 39:2545–2553. [PubMed: 10396623]
27. LeMeur G, et al. Postsurgical assessment and long-term safety of recombinant adeno-associated
virus-mediated gene transfer into the retinas of dogs and primates. Arch. Ophthalmol. 2005;
123:500–506. [PubMed: 15824224]
28. Roman AJ, et al. Quantifying rod photoreceptor-mediated vision in retinal degenerations: dark-
adapted thresholds as outcome measures. Exp. Eye Res. 2005; 80:259–272. [PubMed: 15670804]
29. Daly TM, Vogler C, Levy B, Haskins ME, Sands MS. Neonatal gene transfer leads to widespread
correction of pathology in a murine model of lysosomal storage disease. Proc. Natl. Acad. Sci.
USA. 1999; 96:2296–2300. [PubMed: 10051635]
30. Zolotukhin S, et al. Production and purification of serotype 1, 2 and 5 recombinant adeno-
associated viral vectors. Methods. 2000; 28:158–167. [PubMed: 12413414]
31. Zolotukhin S, et al. Recombinant adeno-associated virus purification using novel methods
improves infectious titer and yield. Gene Ther. 1999; 6:973–985. [PubMed: 10455399]
32. Bennett J, et al. Stable transgene expression in rod photoreceptors after recombinant adeno-
associated virus-mediated gene transfer to monkey retina. Proc. Natl. Acad. Sci. USA. 1999;
96:9920–9925. [PubMed: 10449795]
33. Acland GM, Aguirre GD. Retinal degenerations in the dog: IV. Early retinal degeneration (erd) in
Norwegian elkhounds. Exp. Eye Res. 1987; 44:491. [PubMed: 3496233]
34. Zhang Q, et al. Different RPGR exon ORF15 mutations in canids provide insights into
photoreceptor cell degeneration. Hum. Mol. Genet. 2002; 11:993–1003. [PubMed: 11978759]
35. Adamus G, Zam Z, Arendt A, Palczewski K, McDowell J, Hargrave P. Anti-rhodopsin monoclonal
antibodies of defined specificity: characterization and application. Vision Res. 1991; 31:17–31.
[PubMed: 2006550]
Acland et al. Page 13
Mol Ther. Author manuscript; available in PMC 2013 May 08.
36. Mieziewska K, vanVeen T, Murray J, Aguirre G. Rod and cone specific domains in the
interphotoreceptor matrix. J. Comp. Neurol. 1991; 308:371. [PubMed: 1865006]
Acland et al. Page 14
Mol Ther. Author manuscript; available in PMC 2013 May 08.
FIG. 1.
Short-term (A–C, 1–3 months) and long-term (D–F) restoration of rod and cone retinal
function after a single subretinal treatment of AAV-RPE65. (A) Representative ERGs
evoked by standard white flashes (0.4 log scot-cd s m−2) presented under dark-adapted (DA)
and light-adapted (LA) conditions. DA traces are single flashes, LA traces are averages
obtained at repetition frequencies of 1 (top) and 29 Hz (bottom). Black vertical lines show
the timing of the flashes. Identities of the dogs (BR74, BR61, BR164) refer to Table 1; R,
right eye, L, left eye. ERGs were performed at 3 and 1 months posttreatment in BR61 and
BR164, respectively. (B) ERG photoresponses evoked by white flashes of high energy (3.7
log scot-cd s m−2) under DA and LA conditions, same data are shown on slow (top) and fast
(bottom) time scales to allow interpretation of late and early components, respectively. Gray
lines show the baseline and the 4-ms time point at which rod and cone photoreceptor
responses were measured. (C) Comparison of rod and cone function in the control eyes to
that of the two treatment groups. Rod function shown refers to the DA ERG photoresponse
amplitude at 4 ms and cone function refers to the peak amplitude of the LA 29-Hz
waveform. Each triangle represents an eye. Horizontal dashed lines represent the upper limit
(mean + 3 SD) of the respective measurement in the group of control RPE65−/− affected
eyes (n = 47), which had not received treatment (No Tx). Successful recovery of rod and
cone function is demonstrable in 23/26 (88%; green triangles) of the eyes receiving
subretinal AAV-RPE65 but 0/11 (0%) of the eyes receiving intravitreal AAV-RPE65.
Symbols with error bars show the statistics (means ± SD) for the two control groups. (D)
ERGs evoked by standard white flashes in the right eye of an RPE65 mutant dog (BR33)
before treatment (Pre-Tx) and over a 3-year interval after treatment. Color coding as in B.
(E) ERG photoresponses evoked with white flashes of high energy over the same 3-year
interval in the same eye as in D. Waveforms displayed as in A and B. (F) Two eyes with
subretinal AAV-RPE65 show stable level of partial restoration of retinal rod and cone
function, whereas two eyes with intravitreal AAV-RPE65 show amplitudes similar to those
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of untreated eyes. Horizontal dashed lines represent the upper limit (mean + 3 SD) of the
respective measurement in the group of control RPE65−/− affected eyes, which had not
received treatment.
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FIG. 2.
Chromatographic separation of nonpolar retinoids in retina/RPE–choroid in normal and
untreated and treated RPE65−/− dogs. (A) RPE65+/+ dog (BR140, OS-SC, see
Supplementary Table 1). (B) RPE65−/− affected dog, untreated (BR122 OD-SC, see
Supplementary Table 1). (C) RPE65−/− affected dog treated with AAV-RPE65 (BR74 OD;
C = SN region). Retinoids were extracted from the indicated regions of the eye and
separated on normal-phase HPLC as described under Materials and Methods. The peaks
correspond to the following retinoids: 1, all-trans-retinyl esters; 2 and 2′, syn- and anti-11-
cis-retinal oximes; 3 and 3′, syn-all-trans-retinal oximes; 4, 11-cis-retinol; 5, all-trans-
retinol. *Artifact related to a change in the solvent composition. The syn isomer of syn-11-
cis-retinal oxime is shown in the red box; the expected elution time for syn-11-cis-retinal
oxime is shown by the red arrow; blue arrow indicates expected elution time of syn-9-cis-
retinal oxime. 11-cis-Retinal oximes are present at high level in A, and low level in C, but
not in B. There is dramatic accumulation of retinyl esters in the RPE65−/−affected dog (C)
with or (B) without treatment. (D) Regional variation in nonpolar retinoids in six retinal
sectors from an eye treated in the superior central retina with rAAV-RPE65. Note the
limited diffusion of 11-cis-retinal in the treated eye. Its production is restricted to the site of
subretinal injection (SC). Inset: The spectrum of peak 2 (syn-11-cis-retinal oxime). SC,
superior central; SN, superior nasal; ST, superior temporal; I, inferior.
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FIG. 3.
Retinal photomicrographs of (A, B, G, H) normal, (C, D, I, J) RPE65−/−, and (E, F, K–V)
vector-treated RPE65−/− dogs. Vector-treated animals were (E, F) BR119, right eye, injected
with AAV2/2-CBA-cRPE65 at 3.5 months and sampled at 10.5 months; (K, O–R) BR53,
right eye, injected with AAV2/2-CBA-cRPE65 at 10.5 months and sampled at 17.5 months;
(L, M, N) BR117, left eye, injected with AAV2/5-CBA-hRPE65 at 10 months and sampled
at 2 years; and (S–V) BR53, left eye, injected with AAV2/2-CBA-cRPE65 at 10 months and
sampled at 18 months. As in normal (A, B; 5.5 months), the photoreceptor and outer nuclear
layers are intact in affected (C, D; 3 months) and in vector-treated animals (E, F). Lipoidal
inclusions in the retinal pigment epithelium are prominent in both untreated and treated
affected animals (small oblique arrows in C, E). Normal dogs show intense RPE65
immunolabeling (G, H, green), and peanut agglutinin (PNA; G) and opsin (H) label,
respectively, the extracellular insoluble cone domains and the rod outer segments. The
RPE65−/− dog shows the same pattern of labeling with PNA (I) and opsin (J), but RPE65
immunolabeling is absent. In treated animals, opsin immunolabeling (red) remains
unchanged, but RPE65 labeling is restored (green) and limited to the RPE layer (K, L). (M)
and (N) show low- and high-power views of RPE65 expression in the RPE cell layer and in
one rod photoreceptor (green). (O–R) and (S–V) show that, although the distribution of
expression is more limited in the right retina (O, R) than in the left (S, V), RPE65 labeling is
present in RPE cells but no other cells. Even in areas with intense RPE65 expression,
lipoidal inclusions in the RPE are still present (Q, U, small oblique arrows). All calibration
markers represent 50 Am, marker in F applies to all except N, R, and V.
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